EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications

Julen Viana-Errasti, Raúl Marín, Sandra García-Mulero, Tirso Pons, Mariona Terradas, Gabriel Capellá, Victor Moreno, Pilar Mur, Laura Valle

Modern Pathology · 2025-12 · 38 (12) · 100843

DOI: 10.1016/j.modpat.2025.100843 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Modern Pathology, 2025-12. Verfasst von Julen Viana-Errasti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Exp…. Hauptthemen laut MEDLINE: DNA Polymerase II, DNA Polymerase III, Poly-ADP-Ribose Binding Proteins, Germ-Line Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federación Española de Enfermedades Raras, Agencia Estatal de Investigación, Government of Catalonia Agency for Administration of University and Research Grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polymerases ε and δ maintain genome integrity through exonuclease proofreading. Germline and somatic pathogenic variants (PVs) in the exonuclease domain (ED) of POLE and POLD1 impair proofreading, causing hypermutated tumors. Despite shared mutational features that make these tumors highly immunogenic, molecular and clinical distinctions between POLE and POLD1 mutations and between somatic and germline variants remain incompletely understood. We compared the molecular and clinical characteristics of POLE and POLD1 ED PVs (n = 31), assessing their location, pathogenicity, clinical phenotypes, mismatch repair (MMR) status, tumor mutational burden, and signatures. We analyzed 360 proofreading-deficient tumors (source: The Cancer Genome Atlas [TCGA] and Catalogue Of Somatic Mutations In Cancer [COSMIC]) and 70 families (249 individuals) with polymerase proofreading-associated polyposis. All germline and somatic PVs had high AlphaMissense scores (0.87-1) and clustered within or near Exo motifs. Recurrent, nonfounder germline PVs, POLE L424V and POLD1 S478N, showed low/modest REVEL scores. Somatic variants occurred mainly in endometrial cancers (75% of proofreading-deficient TCGA cancers), whereas colorectal cancer predominated in polymerase proofreading-associated polyposis (56% of carriers). Cancer risks and tumor spectra differed between POLE and POLD1 PV carriers. Aggressive hereditary phenotypes were linked to either specific POLE PVs (eg, S297F, V411L, P436R, M444K, A456P, and S461T) or the co-occurrence of germline ED PVs with germline MMR gene PVs. Distinct hypermutator profiles were confirmed for polymerase ε and polymerase δ proofreading deficiencies via unique mutational signatures (Polymerase ε: SBS10a/b, SBS28; Polymerase δ: SBS10c/d). Tumors with combined proofreading and MMR deficiencies had significantly higher tumor mutational burden and a shift in the associated mutational spectra. Unlike POLE, POLD1 ED PVs exhibited haplosufficiency, typically requiring a somatic second hit (eg, loss of heterozygosity) or MMR deficiency to drive hypermutation. In conclusion, differences between POLE and POLD1 and between somatic and germline mutations influence clinical presentation, mutagenic potential, and reliance on cooperating defects in tumorigenesis. These insights advance the understanding of proofreading-deficient cancers, with implications for diagnostics, genetic counseling, and precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Polymerase IIDNA Polymerase IIIPoly-ADP-Ribose Binding ProteinsGerm-Line MutationNeoplasmsHumansFemaleMaleDNA Mismatch RepairMiddle AgedMutationAdult

Stichwörter der Autor:innen

POLD1POLEhereditary cancermutational signaturespolymerase proofreading-associated polyposistumor mutational burden

Substanzen

DNA Polymerase IIDNA Polymerase IIIPOLD1 protein, humanPOLE protein, humanPoly-ADP-Ribose Binding Proteins

Autor:innen und Institutionen

  • Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobr…
  • Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology, Hospitalet de L…
  • Department of Immunology and Oncology, National Center for Biotechnology (CNB-CSIC), Spanish National Research Council, Madrid, Spain.

Förderung

  • Federación Española de Enfermedades Raras
  • Agencia Estatal de Investigación
  • Government of Catalonia Agency for Administration of University and Research Grants
  • Instituto de Salud Carlos III
  • Government of Catalonia
  • Ministerio de Ciencia e Innovación
  • Institut d'Investigació Biomèdica de Bellvitge
  • NextGenerationEU

Zitieren

APA

Viana-Errasti, J., Marín, R., García-Mulero, S., Pons, T., Terradas, M., Capellá, G., Moreno, V., Mur, P., & Valle, L. (2025). Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications. Modern Pathology, 38(12), 100843. https://doi.org/10.1016/j.modpat.2025.100843

Vancouver

Viana-Errasti J, Marín R, García-Mulero S, Pons T, Terradas M, Capellá G, et al. Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications. Modern Pathology. 2025;38(12):100843. doi:10.1016/j.modpat.2025.100843

BibTeX
@article{VianaErrasti2025,
  author = {Viana-Errasti, Julen and Marín, Raúl and García-Mulero, Sandra and Pons, Tirso and Terradas, Mariona and Capellá, Gabriel and Moreno, Victor and Mur, Pilar and Valle, Laura},
  title = {Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications},
  journal = {Modern Pathology},
  year = {2025},
  volume = {38},
  number = {12},
  pages = {100843},
  doi = {10.1016/j.modpat.2025.100843}
}
Kostenlos starten →